Zoetis Inc. (ZTS) |
| 75.91 0.89 (1.19%) 08-28 09:41 |
| Open: | 75.2 |
| High: | 76.5 |
| Low: | 75.2 |
| Volume: | 166,403 |
| Market Cap: | 31,824(M) |
| PE Ratio: | 11.54 |
| Exchange: | New York Stock Exchange |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 80.17 |
| Resistance 1: | 76.67 |
| Pivot price: | 75.29 |
| Support 1: | 71.00 |
| Support 2: | 59.07 |
| 52w High: | 156.49 |
| 52w Low: | 71 |
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
| EPS | 6.130 |
| Book Value | 0.000 |
| PEG Ratio | 6.87 |
| Gross Profit | 16.529 |
| Profit Margin (%) | 27.68 |
| Operating Margin (%) | 40.72 |
| Return on Assets (ttm) | 15.4 |
| Return on Equity (ttm) | 64.9 |
Thu, 27 Aug 2026
A Look at Zoetis Inc (ZTS) After 3.2% Decline -- GF Value $180.6 - GuruFocus
Tue, 25 Aug 2026
The Bull Case For Zoetis (ZTS) Could Change Following FDA Emergency Use Authorization For Simparica Trio - simplywall.st
Sun, 23 Aug 2026
Zoetis Earnings Reveal a Divided Business, But Can its Pipeline Restore Growth? - Yahoo Finance
Wed, 19 Aug 2026
Zoetis Inc (ZTS) Shares Surge 3.7% -- What GF Score of 64 Tells Investors - GuruFocus
Thu, 06 Aug 2026
Zoetis Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:ZTS) 2026-08-06 - Seeking Alpha
Thu, 06 Aug 2026
Zoetis cuts annual forecasts as pet healthcare demand slows - Reuters
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |